Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9814678 | 0.80 | PGK1 (0.41) | LMNAPTGS2ALDH1A1TP53TDP1 | |
| SCHEMBL7757000 | 0.79 | MEN1 (0.43) | GBA1LMNAMAPTHPGDPTGS1 | |
| SCHEMBL31529664 | 0.77 | MAPT (0.46) | GBA1LMNAMAPTHPGDPTGS1 | |
| SCHEMBL299924 | 0.77 | MAPT (0.46) | GBA1LMNAMAPTHPGDPTGS1 | |
| SCHEMBL1081178 | 0.77 | HRH3 (0.36) | CYP3A4 | |
| SCHEMBL20327221 | 0.76 | GBA1 (0.43) | GBA1LMNAMAPTHPGDPTGS1 | |
| SCHEMBL6752527 | 0.76 | TP53 (0.55) | PTGS1PTGS2ALDH1A1TP53TDP1 | |
| SCHEMBL2754745 | 0.76 | SLC6A3 (0.36) | PTGS2ALDH1A1TP53TDP1CYP3A4 | |
| SCHEMBL7977708 | 0.76 | GBA1 (0.40) | GBA1LMNAMAPTHPGDPTGS1 | |
| SCHEMBL167439 | 0.73 | FURIN (0.43) | LMNAMAPTTDP1L3MBTL1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664277-B1 | METHOD OF PREPARATION OF PHARMACEUTICALLY GRADE PLASMID DNA | AVENTIS PHARMA SA (FR) | 2011-11-09 | — | — | EP | disclosed |
| EP-1737945-B1 | METHOD FOR PURIFYING PLASMID DNA | AVENTIS PHARMA SA (FR) | 2011-01-26 | — | — | EP | disclosed |
| EP-2246413-A2 | Method for purifying plasmid DNA having pharmaceutical quality | CENTELION (FR) | 2010-11-03 | — | — | EP | disclosed |
| US-20070213289-A1 | Method for purifying plasmid DNA | CENTELION (FR) | 2007-09-13 | — | — | US | disclosed |
| EP-1791945-A1 | STABLE LIQUID FORMULATIONS OF PLASMID DNA | CENTELION (FR) | 2007-06-06 | — | — | EP | disclosed |
| US-20070111221-A1 | Method of preparation for pharmaceutical grade plasmid DNA | AVENTIS PHARMA S.A. (FR) | 2007-05-17 | — | — | US | disclosed |
| EP-1737945-A1 | METHOD FOR PURIFYING PLASMID DNA | CENTELION (FR) | 2007-01-03 | — | — | EP | disclosed |
| EP-1664277-A2 | METHOD OF PREPARATION OF PHARMACEUTICALLY GRADE PLASMID DNA | CENTELION (FR) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006029908-A1 | STABLE LIQUID FORMULATIONS OF PLASMID DNA | CENTELION (FR) | 2006-03-23 | — | — | WO | disclosed |
| WO-2005100542-A1 | METHOD FOR PURIFYING PLASMID DNA | CENTELION (FR) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005026331-A2 | METHOD OF PREPARATION OF PHARMACEUTICALLY GRADE PLASMID DNA | CENTELION (FR) | 2005-03-24 | — | — | WO | disclosed |
| EP-0964057-B1 | Method for separating nucleic acids by means of liquid chromatography | TOSOH CORP (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-6441160-B2 | HYDROPHOBIC INTERACTION CHROMATOGRAPHY USING PACKING MATERIAL WITH FUNCTIONAL GROUP INTRODUCED TO ADSORB NUCLEIC ACIDS THAT EXHIBIT CERTAIN HYDROPHOBICITY | TOSOH CORPORATION (JP) | 2002-08-27 | — | — | US | disclosed |
| US-20010007026-A1 | METHOD OF SEPARATING NUCLEIC ACIDS BY MEANS OF LIQUID CHROMATOGRAPHY | TOSOH CORPORATION (JP) | 2001-07-05 | — | — | US | disclosed |
| EP-0964057-A1 | Method for separating nucleic acids by means of liquid chromatography | TOSOH CORPORATION (JP) | 1999-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007026-A1 | METHOD OF SEPARATING NUCLEIC ACIDS BY MEANS OF LIQUID CHROMATOGRAPHY | DNA2, HNRNPH3, POLRMT | GBA1 1952/4885LMNA 80/4885MAPT 3692/4885 |
| US-20070213289-A1 | Method for purifying plasmid DNA | DNASE1, POLL, DNASE1L3 | GBA1 1416/4885LMNA 40/4885MAPT 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.